MCID: PRS040
MIFTS: 84

Prostate Cancer malady

Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases categories

Aliases & Classifications for Prostate Cancer

About this section
Sources:
45OMIM, 30LifeMap Discovery®, 9Disease Ontology, 10diseasecard, 41NIH Rare Diseases, 20GeneTests, 11DISEASES, 43Novoseek, 47Orphanet, 22GTR, 32MedlinePlus, 3CDC, 60UMLS, 55SNOMED-CT, 33MeSH, 38NCIt, 34MESH via Orphanet, 26ICD10 via Orphanet, 61UMLS via Orphanet, 25ICD10
See all sources

Prostate Cancer, Aliases & Descriptions:

Name: Prostate Cancer 45 30 9 10 11 43 32 3
Prostate Cancer, Familial 45 9 41 60
Prostate Carcinoma 9 43 60
Malignant Tumor of the Prostate 9 22
Prostate Cancer, Hereditary, 5 45 10
Prostate Cancer, Hereditary 45 41
Hereditary Prostate Cancer 9 41
Familial Prostate Cancer 41 47
Carcinoma of Prostate 9 20
Prostate Cancer, Progression of 45
Malignant Neoplasm of Prostate 60
 
Ngp - New Growth of Prostate 9
Prostate Cancer, Somatic 45
Prostate Cancer Somatic 45
Tumor of the Prostate 9
Prostatic Neoplasms 60
Prostatic Neoplasm 9
Cancer of Prostate 9
Prostate Cancer 3 45
Prostate Cancer 4 45
Prostate Neoplasm 9
Prostatic Cancer 9


Classifications:



Characteristics (Orphanet epidemiological data):

47
familial prostate cancer:
Prevalence: 1-9/100000 (United States); Age of onset: Adult


External Ids:

OMIM45 176807
Disease Ontology9 DOID:10283, DOID:10286
NCIt38 C3343, C4863
Orphanet47 1331
MESH via Orphanet34 C537243
ICD10 via Orphanet26 C61
UMLS via Orphanet61 C2931456
ICD1025 C61

Summaries for Prostate Cancer

About this section


MedlinePlus:32 The prostate is the gland below a man's bladder that produces fluid for semen. prostate cancer is common among older men. it is rare in men younger than 40. risk factors for developing prostate cancer include being over 65 years of age, family history, and being african-american. symptoms of prostate cancer may include problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling low back pain pain with ejaculation to diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. you may also get a blood test for prostate-specific antigen (psa). these tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. if your results are abnormal, you may need more tests, such as an ultrasound, mri, or biopsy. treatment often depends on the stage of the cancer. how fast the cancer grows and how different it is from surrounding tissue helps determine the stage. men with prostate cancer have many treatment options. the treatment that's best for one man may not be best for another. the options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. you may have a combination of treatments. nih: national cancer institute

MalaCards based summary: Prostate Cancer, also known as prostate cancer, familial, is related to adenocarcinoma and breast cancer, and has symptoms including autosomal dominant inheritanceand prostate cancer. An important gene associated with Prostate Cancer is AR (androgen receptor), and among its related pathways are Integrated Breast Cancer Pathway and Integrated Pancreatic Cancer Pathway. The drugs aminoglutethimide and chlorotrianisene and the compounds testosterone and serine have been mentioned in the context of this disorder. Affiliated tissues include the prostate, prostate and bone, and related mouse phenotypes are endocrine/exocrine gland and reproductive system.

Disease Ontology:9 A male reproductive organ cancer that is located in the prostate.

CDC:3 Prostate cancer is the most common cancer among American men. Most prostate cancers grow slowly, and don’t cause any health problems in men who have them.

Novus Biologicals:44 Prostate cancer is the most common non-skin cancer and second most deadly cancer for men in the United States. Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. If untreated, cells from these tumors can spread via metastasis. Metastasis transports prostate cancer cells through the lymphatic system and bloodstream to other parts of the body where they can grow into secondary tumors. PSA, a protein produced by the prostate, is released into the bloodstream in small amounts under normal conditions. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer.

Wikipedia:63 Prostate cancer, also known as carcinoma of the prostate, is the development of cancer in the prostate,... more...

Description from OMIM:45 176807

Related Diseases for Prostate Cancer

About this section

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 12 Prostate Cancer, Hereditary, 10
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 14
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 2
Prostate Cancer, Hereditary, 11 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 15 Prostate Cancer 1
Prostate Carcinoma in Situ

Diseases related to Prostate Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 309)
idRelated DiseaseScoreTop Affiliating Genes
1adenocarcinoma32.4MXI1, PTEN, CHEK2, AR, MSMB, CDH1
2breast cancer32.1AR, BRCA2, CDH1
3prostatic hypertrophy32.0AR, MXI1
4androgen insensitivity31.9AR, SRD5A2
5gynecomastia31.9SRD5A2, BRCA2, AR
6leukemia31.9MXI1, RNASEL, BRCA2, CHEK2, CD82
7retinoblastoma31.8CHEK2, AR, BRCA2, KLF6
8melanoma31.8CHEK2, MXI1, CD82, CDH1, PTEN, BRCA2
9colorectal cancer31.6KLF6, CD82, CDH1, PTEN
10glioblastoma31.5PTEN, MXI1, EPHB2, CHEK2, KLF6
11bilateral breast cancer31.3BRCA2, CHEK2
12hepatocellular carcinoma31.2CD82, PTEN, BRCA2, SRD5A2, KLF6, CDH1
13li-fraumeni syndrome31.0PTEN, BRCA2, CHEK2
14lung cancer30.9KLF6, CD82, CDH1, PTEN
15prostatitis12.0
16endotheliitis11.0
17ovarian cancer, somatic10.9PTEN, BRCA2, RNASEL, EPHB2, CHEK2, MSR1
18hypoxia10.9
19insulin-like growth factor i10.8
20gastric cancer, somatic10.8CD82, PTEN, ZFHX3, BRCA2, EPHB2, CHEK2
21stomach cancer10.7CD82, PTEN, CHEK2, CDH1
22brain cancer10.7PTEN, MXI1, KLF6, EPHB2
23follicular adenoma10.7CDH1, PTEN, AR
24penis agenesis10.7SRD5A2, AR
25alopecia, androgenetic, 110.7AR, SRD5A2
26obesity10.7
27prostate disease10.6
28pseudohermaphroditism10.6SRD5A2, AR
29cowden disease10.6BRCA2, PTEN
30prostate cancer 110.6
31proctitis10.6
32ductal carcinoma in situ10.6CDH1, BRCA2
33breast ductal carcinoma10.6CDH1, AR
34blindness10.6
35peutz-jeghers syndrome10.5PTEN, BRCA2
36hypospadias10.5AR, SRD5A2
37osteoporosis10.5
38hypogonadism10.5
39endometrial cancer10.5CDH1, PTEN
40chronic fatigue syndrome10.5
41disseminated intravascular coagulation10.5
42neuronitis10.5
43neuroectodermal tumor10.5
44adenoma10.4
45alopecia10.4
46urethritis10.4
47impotence10.4
48radiation proctitis10.4
49vaccinia10.4
50herpes simplex10.4

Graphical network of the top 20 diseases related to Prostate Cancer:



Diseases related to prostate cancer

Symptoms for Prostate Cancer

About this section

Symptoms by clinical synopsis from OMIM:

176807

Clinical features from OMIM:

176807

HPO human phenotypes related to Prostate Cancer:

id Description Frequency HPO Source Accession
1 autosomal dominant inheritance HP:0000006
2 prostate cancer HP:0012125

Drugs & Therapeutics for Prostate Cancer

About this section

Genetic Tests for Prostate Cancer

About this section

Genetic tests related to Prostate Cancer:

id Genetic test Affiliating Genes
1 Prostate Cancer20 SRD5A2
2 Malignant Tumor of Prostate22

Anatomical Context for Prostate Cancer

About this section

MalaCards organs/tissues related to Prostate Cancer:

31
Prostate, Bone, Breast, Endothelial, Lymph node, Testes, Skin, T cells, Bone marrow, Lung, Pituitary, Liver, Testis, Colon, Brain, Kidney, Monocytes, Heart, Myeloid, Nk cells, B cells, Adipocyte, Placenta, Spinal cord, Eye, Whole blood, Pancreas, Thyroid, Salivary gland, Ovary, Cervix, Tongue, Pineal

FMA organs/tissues related to Prostate Cancer:

14
The prostate

Animal Models for Prostate Cancer or affiliated genes

About this section

MGI Mouse Phenotypes related to Prostate Cancer:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537911.7AR, HOXB13, PTEN, ZFHX3, BRCA2, EPHB2
2MP:000538911.7HOXB13, PTEN, ZFHX3, BRCA2, EPHB2, MSMB
3MP:000538411.6RNASEL, BRCA2, PTEN, HOXB13, EPHB2, CHEK2
4MP:001076811.6EPHB2, BRCA2, ZFHX3, PTEN, CHEK2, MSR1
5MP:000200611.5PTEN, ZFHX3, BRCA2, CHEK2, MSMB, MAD1L1
6MP:000538711.3PTEN, BRCA2, RNASEL, CHEK2, MSR1, MSMB
7MP:000539711.1PTEN, BRCA2, RNASEL, CHEK2, MSR1, KLF6
8MP:000538011.0AR, CDH1, KLF6, BRCA2, PTEN, HOXB13
9MP:001077110.7HOXB13, PTEN, BRCA2, KLF6, CDH1, AR

Publications for Prostate Cancer

About this section

Articles related to Prostate Cancer:

(show top 50)    (show all 11015)
idTitleAuthorsYear
1
Re: Effect of Soy Protein Isolate Supplementation on Biochemical Recurrence ofA Prostate Cancer after Radical Prostatectomy: A Randomized Trial. (24331479)
2014
2
Lumican expression, localization and antitumor activity in prostate cancer. (23399832)
2013
3
Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. (23676682)
2013
4
Pre-prostatic tissue removed in robotic assisted lymph node dissection for prostate cancer contains lymph nodes. (24311906)
2013
5
Pre-chemotherapy Abiraterone Acetate. A Proposal of a Treatment Algorithm in Castration Resistant Prostate Cancer. (24342031)
2013
6
No evidence of FGFR3 mutations in prostate cancer. (20957671)
2011
7
PPARI^ disease gene network and identification of therapeutic targets for prostate cancer. (21780947)
2011
8
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. (19820934)
2010
9
Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF- kappaB activity in prostate cancer cells. (20068069)
2010
10
CYP17 polymorphisms and prostate cancer outcomes. (20503394)
2010
11
Promising tumor-associated antigens for future prostate cancer therapy. (19536865)
2010
12
Other biomarkers for detecting prostate cancer. (19930175)
2010
13
Investigative clinical study on prostate cancer part III: exploring total PSA and free testosterone distributions and linear correlations in groups and subgroups of operated prostate cancer patients according to the total PSA/FT ratio. (20948186)
2010
14
Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. (18762814)
2009
15
Y chromosome haplotypes and prostate cancer in Sweden. (18927315)
2008
16
A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. (18703514)
2008
17
Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk: a replication study in an ethnically homogeneous population. (18537123)
2008
18
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. (18628469)
2008
19
P2Y purinergic receptor activated PI-3K/Akt signaling pathway in regulation of growth and invasion of prostatic cancer]. (18194602)
2007
20
Locally advanced prostate cancer: biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. (17559131)
2007
21
Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. (16698360)
2006
22
Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. (16388505)
2006
23
Characterization of frequently deleted 6q locus in prostate cancer. (17132090)
2006
24
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. (16461912)
2006
25
Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer. (16161052)
2006
26
Targeting stathmin in prostate cancer. (16373697)
2005
27
A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies. (15727931)
2005
28
Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. (16005185)
2005
29
An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. (15266311)
2004
30
Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. (15280008)
2004
31
Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events. (15390081)
2004
32
Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer. (15492805)
2004
33
Vitamin D receptor gene Bsm I polymorphism and the susceptibility to prostate cancer in northern Chinese Han population]. (14574802)
2003
34
A comparative study of prostate specific antigen (PSA), C-terminal propeptide of blood type I procollagen (PICP) and urine type I collagen-crosslinked N telopeptide (NTx) levels using bone scintigraphy in prostate cancer patients. (12932112)
2003
35
Metastatic prostate cancer with normal level of serum prostate-specific antigen. (15072491)
2003
36
A candidate prostate cancer susceptibility gene encodes tRNA 3' processing endoribonuclease. (12711671)
2003
37
Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. (14695191)
2003
38
Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells. (11956160)
2002
39
Inhibition of nuclear factor kappaB induces apoptosis following treatment with tumor necrosis factor alpha and an antioxidant in human prostate cancer cells. (12269771)
2002
40
The peroxisome proliferator-activated receptor gamma ligand 15-deoxy-Delta12,14-prostaglandin J2 induces vascular endothelial growth factor in the hormone-independent prostate cancer cell line PC 3 and the urinary bladder carcinoma cell line 5637. (12239635)
2002
41
Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells. (11228105)
2001
42
Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. (11746273)
2001
43
A novel human cancer culture model for the study of prostate cancer. (11753687)
2001
44
Contrasting effects of aspirin on prostate cancer cells: suppression of proliferation and induction of drug resistance . (10639187)
2000
45
BRCA1 and BRCA2 have a limited role in familial prostate cancer. (10728701)
2000
46
Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. (10475365)
1999
47
The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. (10545066)
1999
48
Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer. (9592622)
1998
49
NGF-beta, NE-cells and prostatic cancer cell lines. A study of neuroendocrine expression in the human prostatic cancer cell lines DU-145, PC-3, LNCaP, and TSU-pr1 following stimulation of the nerve growth factor-beta. (9561567)
1998
50
Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer? (9179191)
1997

Variations for Prostate Cancer

About this section

UniProtKB/Swiss-Prot genetic disease variations for Prostate Cancer:

62 (show all 22)
id Symbol AA change Variation ID SNP ID
1CHEK2p.Arg180CysVAR_019103rs77130927
2CHEK2p.Arg181CysVAR_019104rs137853010
3CHEK2p.Arg181HisVAR_019105rs121908701
4CHEK2p.Glu239LysVAR_019106
5CHEK2p.Glu64LysVAR_019107
6CHEK2p.Arg145ProVAR_019108
7CHEK2p.Gly167ArgVAR_019109
8CHEK2p.Arg180HisVAR_019110rs137853009
9CHEK2p.Ile251PheVAR_019111
10CHEK2p.Arg318HisVAR_019112rs143611747
11CHEK2p.Thr323ProVAR_019113
12CHEK2p.Tyr327CysVAR_019114
13CHEK2p.Thr476LysVAR_019115
14EPHB2p.Arg199HisVAR_032853
15EPHB2p.Ala279SerVAR_032854rs35882952
16EPHB2p.Val650AlaVAR_032855rs142173175
17EPHB2p.His679AsnVAR_032856
18EPHB2p.Met883ValVAR_032857
19EPHB2p.Ile909MetVAR_032858
20HOXB13p.Gly84GluVAR_071866
21MXI1p.Glu152AlaVAR_004499
22PTENp.Met134LeuVAR_007469

Clinvar genetic disease variations for Prostate Cancer:

6 (show all 28)
id Gene Variation Type Significance SNP ID Assembly Location
1RNASELNM_021133.3(RNASEL): c.793G> T (p.Glu265Ter)single nucleotide variantPathogenicrs74315364GRCh37Chr 1, 182555149: 182555149
2RNASELNM_021133.3(RNASEL): c.3G> A (p.Met1Ile)single nucleotide variantPathogenicrs74315365GRCh37Chr 1, 182555939: 182555939
3EHBP1NM_001142615.2(EHBP1): c.1185+30064G> Asingle nucleotide variantPathogenicrs721048GRCh37Chr 2, 63131731: 63131731
4MSMBNM_002443.3(MSMB): c.-89T=single nucleotide variantPathogenicrs10993994GRCh37Chr 10, 51549496: 51549496
5MSR1NM_138715.2(MSR1): c.877C> T (p.Arg293Ter)single nucleotide variantPathogenicrs41341748GRCh37Chr 8, 16012594: 16012594
6MSR1NM_138715.2(MSR1): c.520G> T (p.Asp174Tyr)single nucleotide variantPathogenicrs72552387GRCh37Chr 8, 16026077: 16026077
7ZFHX3ZFHX3, 24-BP DEL, NT10814deletionPathogenic
8ELAC2NM_018127.6(ELAC2): c.650C> T (p.Ser217Leu)single nucleotide variantPathogenicrs4792311GRCh37Chr 17, 12915009: 12915009
9ELAC2NM_018127.6(ELAC2): c.1621G> A (p.Ala541Thr)single nucleotide variantPathogenicrs5030739GRCh37Chr 17, 12899902: 12899902
10ELAC2NM_018127.6(ELAC2): c.1641dupG (p.His548Alafs)duplicationPathogenicrs387906327GRCh37Chr 17, 12899881: 12899882
11ELAC2NM_018127.6(ELAC2): c.2342G> A (p.Arg781His)single nucleotide variantPathogenicrs119484086GRCh37Chr 17, 12896274: 12896274
12ELAC2NM_018127.6(ELAC2): c.1865A> T (p.Glu622Val)single nucleotide variantPathogenicrs119484087GRCh37Chr 17, 12898323: 12898323
13EPHB2NM_004442.6(EPHB2): c.2167C> T (p.Gln723Ter)single nucleotide variantPathogenicrs121912582GRCh37Chr 1, 23234473: 23234473
14EPHB2NM_004442.6(EPHB2): c.835G> T (p.Ala279Ser)single nucleotide variantPathogenicrs35882952GRCh37Chr 1, 23189553: 23189553
15EPHB2NM_004442.6(EPHB2): c.2035G> A (p.Asp679Asn)single nucleotide variantPathogenicrs28936395GRCh37Chr 1, 23233346: 23233346
16EPHB2NM_004442.6(EPHB2): c.*187A> Tsingle nucleotide variantrisk factorrs76826147GRCh37Chr 1, 23240250: 23240250
17BRCA2BRCA2, 1-BP DEL, 6051AdeletionPathogenic
18BRCA2BRCA2, 1-BP INS, 2558AinsertionPathogenic
19MXI1MXI1, 1-BP DEL, A, CODON 140 OR 141deletionPathogenic
20MXI1NM_130439.3(MXI1): c.552+2T> Csingle nucleotide variantPathogenicrs387906417GRCh37Chr 10, 112039054: 112039054
21MXI1NM_130439.3(MXI1): c.656A> C (p.Glu219Ala)single nucleotide variantPathogenicrs137852603GRCh37Chr 10, 112039775: 112039775
22ARNM_000044.3(AR): c.1943G> A (p.Ser648Asn)single nucleotide variantPathogenicrs137852584GRCh37Chr X, 66931301: 66931301
23ARNM_000044.3(AR): c.2191G> A (p.Val731Met)single nucleotide variantPathogenicrs137852571GRCh37Chr X, 66937337: 66937337
24ARNM_000044.3(AR): c.2632A> G (p.Thr878Ala)single nucleotide variantPathogenicrs137852578GRCh37Chr X, 66943552: 66943552
25ARNM_000044.3(AR): c.2633C> G (p.Thr878Ser)single nucleotide variantPathogenicrs137852580GRCh37Chr X, 66943553: 66943553
26ARNM_000044.3(AR): c.2623C> T (p.His875Tyr)single nucleotide variantPathogenicrs137852581GRCh37Chr X, 66943543: 66943543
27ARNM_000044.3(AR): c.2708A> G (p.Gln903Arg)single nucleotide variantPathogenicrs137852582GRCh37Chr X, 66943628: 66943628
28ARNM_000044.3(AR): c.2164G> A (p.Ala722Thr)single nucleotide variantPathogenicrs137852583GRCh37Chr X, 66931522: 66931522

Cosmic variations for Prostate Cancer:

7
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1763PIK3CAskin,back,carcinoma,basal cell carcinoma1

Expression for genes affiliated with Prostate Cancer

About this section
Search GEO for disease gene expression data for Prostate Cancer.

Pathways for genes affiliated with Prostate Cancer

About this section

Pathways related to Prostate Cancer according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
111.0AR, CDH1, CHEK2, BRCA2, PTEN
211.0AR, CD82, CHEK2, BRCA2, PTEN
3
Show member pathways
Signaling Pathways in Glioblastoma36
11.0PTEN, BRCA2, SRD5A2, CDH1, AR
410.9PTEN, BRCA2, CDH1, AR
5
Show member pathways
Prostate Cancer36
Integrated Cancer pathway36
Steroid Biosynthesis36
10.8AR, CHEK2, PTEN
6
Show member pathways
Cell cycle36
10.8CDH1, MAD1L1, CHEK2
7
Show member pathways
Translation Non genomic rapid action of Androgen Receptor58
10.8AR, SRD5A2, PTEN
8
Show member pathways
DNA damage response36
10.8PTEN, CHEK2, CD82

Compounds for genes affiliated with Prostate Cancer

About this section

Compounds related to Prostate Cancer according to GeneCards Suite gene sharing:

(show all 39)
idCompoundScoreTop Affiliating Genes
1testosterone43 59 24 1214.7AR, PTEN, BRCA2, RNASEL, MSR1, MSMB
2serine4311.6PTEN, EPHB2, CHEK2, ELAC2, MAD1L1, KLF6
3tyrosine4311.5PTEN, EPHB2, CHEK2, MSR1, MSMB, CD82
4arginine4311.4PTEN, RNASEL, EPHB2, SRD5A2, CDH1, AR
5phosphatidylinositol4311.4PTEN, BRCA2, EPHB2, CHEK2, CDS1, CDH1
6estrogen4311.4PTEN, BRCA2, SRD5A2, KLF6, CDH1, AR
7retinoic acid43 2412.4PTEN, BRCA2, EPHB2, CHEK2, CDH1, AR
8etoposide43 49 59 1214.4PTEN, BRCA2, CHEK2, CDH1, AR
9genistein43 28 59 2 24 1216.4PTEN, BRCA2, CHEK2, CDH1, AR
10paraffin4311.4PTEN, BRCA2, CD82, CDH1, AR
11progesterone43 28 59 24 1215.3PTEN, BRCA2, SRD5A2, CDH1, AR
12steroid4311.3AR, SRD5A2, MSMB, BRCA2, PTEN
13indole-3-carbinol4311.3PTEN, BRCA2, CDH1, AR
14adenine43 24 1213.3RNASEL, SRD5A2, CDH1, AR
15n acetylcysteine4311.2CHEK2, MSR1, CDH1, AR
16tamoxifen43 49 28 1214.2AR, CDH1, BRCA2, PTEN
17vitamin d4311.2PTEN, SRD5A2, CDH1, AR
18paclitaxel43 49 1213.2PTEN, BRCA2, MAD1L1, CDH1
19rapamycin4311.2PTEN, CHEK2, CDH1, AR
20doxorubicin43 49 1213.2PTEN, CHEK2, CDH1, AR
21estradiol43 24 1213.2PTEN, BRCA2, SRD5A2, AR
22glutamine4311.1AR, CDH1, SRD5A2, BRCA2
23nocodazole43 1212.1CDH1, MAD1L1, CHEK2
24adriamycin4311.1CDH1, CHEK2, BRCA2
25troglitazone43 28 59 1214.1PTEN, CDH1, AR
26dutasteride43 1212.0AR, SRD5A2
27cisplatin43 49 59 1214.0CDH1, CHEK2, BRCA2, PTEN
28docetaxel43 49 59 1214.0BRCA2, CDH1, AR
29leucine4311.0PTEN, SRD5A2, MXI1, CDH1
30mg 13243 5912.0PTEN, CDH1, AR
31dihydrotestosterone43 28 24 1214.0SRD5A2, CDH1, AR
32sodium bisulfite4310.9AR, CDH1
33finasteride43 59 24 1213.9SRD5A2, AR
345-aza-2deoxycytidine4310.9AR, CDH1, PTEN
35adenylate4310.9RNASEL, KLF6, CDH1, AR
36calcitriol43 59 24 1213.8AR, CDH1, PTEN
37danazol43 24 1212.7AR, CDH1
38o6-methylguanine4310.6CDH1, BRCA2
39cycloheximide4310.6PTEN, BRCA2, RNASEL, AR

GO Terms for genes affiliated with Prostate Cancer

About this section

Cellular components related to Prostate Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nucleusGO:000563411.4PTEN, ZFHX3, BRCA2, ELAC2, MSMB, MAD1L1
2Schmidt-Lanterman incisureGO:004322010.4CDH1, PTEN

Biological processes related to Prostate Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of transcription, DNA-templatedGO:004589311.0AR, CDH1, KLF6, CHEK2, BRCA2
2response to gamma radiationGO:001033210.7CHEK2, BRCA2
3dendritic spine morphogenesisGO:006099710.6PTEN, EPHB2
4negative regulation of axonogenesisGO:005077110.4EPHB2, PTEN

Products for genes affiliated with Prostate Cancer

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies
  • Proteins
  • Kits and Assays

Sources for Prostate Cancer

About this section
3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCIt
39NDF-RT
42NINDS
43Novoseek
45OMIM
46OMIM via Orphanet
50PubMed
51QIAGEN
56SNOMED-CT via Orphanet
60UMLS
61UMLS via Orphanet